Phenylketonuria

D'Eustachio, P., Jassal, B.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license.

30/05/2021
Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references


Reactome database release: 76

This document contains 1 pathway and 1 reaction (see Table of Contents)
Phenylketonuria

Stable identifier: R-HSA-2160456

Diseases: phenylketonuria

Phenylalanine hydroxylase (PAH) normally catalyzes the conversion of phenylalanine to tyrosine. In the absence of functional PAH, phenylalanine accumulates to high levels in the blood and is converted to phenylpyruvate and phenyllactate (Clemens et al. 1990; Langenbeck et al. 1992; Mitchell et al. 2011). The extent of these conversions is modulated by genetic factors distinct from PAH, as siblings with the identical PAH defect can produce different amounts of them (Treacy et al. 1996).

Both L-amino acid oxidase (Boulland et al. 2004) and Kynurenine--oxoglutarate transaminase 3 (Han et al. 2004) can catalyze the conversion of phenylalanine to phenylpyruvate and lactate dehydrogenase can catalyze the conversion of the latter molecule to phenyllactate (Meister 1950), in reactions not annotated here.

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012-03-05</td>
<td>Authored</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2012-03-16</td>
<td>Edited</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2012-03-16</td>
<td>Reviewed</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-01-28</td>
<td>Revised</td>
<td>Jassal, B.</td>
</tr>
</tbody>
</table>
Defective PAH does not hydroxylate L-Phe to L-Tyr

**Location:** Phenylketonuria

**Stable identifier:** R-HSA-5649483

**Type:** transition

**Compartments:** cytosol

**Diseases:** phenylketonuria

Inactivating mutations of cytosolic phenylalanine hydroxylase (PAH) block the normal reaction of phenylalanine, molecular oxygen and tetrahydrobiopterin to form tyrosine, water, and 4 alpha-hydroxy-tetrahydrobiopterin. Excess phenylalanine accumulates as a result, driving the formation of abnormally high levels of phenylpyruvate, and phenyllactate (Guldberg et al. 1996; Mitchell et al. 2011) in reactions not annotated here.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-12-08</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-01-28</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
</tbody>
</table>
# Table of Contents

- **Introduction**  
- **Phenylketonuria**  
  - Defective PAH does not hydroxylate L-Phe to L-Tyr  
- Table of Contents